Market Data Current As Of: September 12, 2026
Related Competitor Intelligence
Compare market positioning with top industry peers
Explore Amgen
Core profile pages, annual revenue records, and related research hubs for this company.
Compare market positioning with top industry peers
Explore Amgen
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$36.8B
Market Cap
$168.4B
Net Income
$7.7B
Employees
26,743
Amgen's financial narrative in 2026 is defined by its aggressive expansion into rare diseases and its high-stakes entry into the lucrative obesity market. Under CEO Robert A. Bradway, the biotechnology giant commands a $168.4 billion market cap, generating exactly $28.2 billion in revenue with exactly 26743 employees. Amgen has integrated its $27.8 billion acquisition of Horizon Therapeutics, which expanded its rare disease portfolio (anchored by the blockbuster thyroid eye disease drug Tepezza) and offset the revenue erosion from its older legacy drugs facing biosimilar competition. the company is funneling R&D capital into its clinical pipeline, racing to capture market share in the red-hot GLP-1 weight-loss sector with its anticipated clinical asset, MariTide.
Revenue Trend Analysis
YoY Change
+10%
5-Year CAGR
+7.6%
Peak Year
2025
Trend
Consistent Growth
Amgen Inc. has reported revenue across 6 fiscal years, compounding at +7.6% annually over 5 years. The most recent year saw a 10% increase versus the prior year. Revenue peaked in 2025 at $36.8B. Out of 5 reported periods, 5 showed growth and 0 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $36.8B | $7.7B | +10.0% |
| FY2024 | $33.4B | — | +18.6% |
| FY2023 | $28.2B | — | +7.1% |
| FY2022 | $26.3B | — | +1.3% |
| FY2021 | $26.0B | — | +2.2% |
| FY2020 | $25.4B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Amgen Inc. reported approximately $28.2B in fiscal year 2025 with a team of 26,743 employees worldwide.
Amgen Inc. strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.
Financial performance in Biotechnology / Biopharmaceuticals is driven by steady cash generation and pricing power, enabling Amgen Inc. to reinvest in high-return strategic initiatives.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Amgen Inc. Revenue & Financials." CorpDigest, https://corpdigest.com/company/amgen/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Amgen Inc. reported $37B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/amgen/financials" target="_blank" rel="noopener">CorpDigest — Amgen Inc. financials</a></div>